GIP and GLP-1 receptor co-agonist
VK2735 10 mg injection once weekly
VK2735_SC_10MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.54 (0.18 to 11.96) | 0.43 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.43 (0.71 to 31.52) | 0.30 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.89 (0.76 to 4.92) | 0.75 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.46 (1.17 to 32.98) | 0.41 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.15 (0.62 to 8.29) | 0.45 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.09 (0.59 to 7.30) | 0.48 |
| Overweight or obesity without diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 0.37 (0.01 to 13.19) | 0.73 |